ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Enveda Biosciences has raised $51 million in series A funding to develop small-molecule therapies from plants. The funding round was led by Lux Capital. Enveda is creating what it calls the first high-resolution chemical map of the natural world, and applying machine learning and metabolomics to predict novel chemistry. The company hopes to identify candidate molecules to treat diseases such as nonalcoholic steatohepatitis and Parkinson’s disease.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X